DL

Daniel Lynch

Executive Venture Partner @GVteam

Boston, Massachusetts

Investor
VC

Invests in

Stages:

Series A
Seed

  • Min Investment:

    $250,000.00

  • Max Investment:

    $50,000,000.00

  • Target Investment:

    $25,000,000.00

Education

Investments

Tome Biosciences

Series A

Total Funding: $210M

Blueprint Medicines

Series B

Total Funding: $65M

Sesen Bio

Series A

Total Funding: $55M

Work Experience

Xilio, SpringWorks, bluebird, Blueprint, Translate

2008

  • Chairman of the Board

    2008

Xilio Therapeutics, Inc.

2020

  • Chairman Of The Board

    2020

SpringWorks Therapeutics

2017

  • Chairman of the Board

    2017

Blueprint Medicines

2012

  • Chairman Of The Board

    2012

Translate Bio

2012

  • Chairman Of The Board

    2012

bluebirdbio

2011

  • Chairman of the Board

    2011

Surface Oncology Inc.

2017 - 2021

  • Chairman Of The Board

    2017 - 2021

BIND Therapeutics

2012 - 2016

  • Chairman of the Board

    2012 - 2016

Nimbus Discovery

2012 - 2015

  • Executive Chairman

    2012 - 2015

Ember Therapeutics

2012 - 2013

  • Board Member

    2012 - 2013